In reply: We thank Lam for pointing out an error in the referencing in Box 3 of our article1 regarding the figures for adverse events for donepezil. The correct reference was number 48 in our list, not 49, and was to Rogers, Farlow, Doody et al,2 not to Rogers and Friedhoff,3 as suggested by Lam. The other references in Box 3 were given as 20, 21, 23 and 48, but should have been listed as 19, 20, 21 and 47, respectively.
The full article is accessible to AMA members and paid subscribers. Login to read more or purchase a subscription now.
Please note: institutional and Research4Life access to the MJA is now provided through Wiley Online Library.
- 1 Academic Department for Old Age Psychiatry, Prince of Wales Hospital, Randwick, NSW.
- 2 Memory Disorders Study Unit, Repatriation General Hospital, Daw Park, SA.
- 3 Department of Psychological Medicine, University of Sydney, Rozelle Hospital, Leichhardt, NSW.
- 4 Department of Old Age Psychiatry, University of Melbourne, Royal Melbourne Hospital, VIC.
- 5 School of Psychiatry, University of New South Wales.
- 1. Brodaty H, Ames D, Boundy KL, et al. Pharmacological treatment of cognitive deficits in Alzheimer's disease [review]. Med J Aust 2001; 175: 324-329.
- 2. Rogers SL, Farlow MR, Doody RS, et al. A 24-week, double-blind, placebo-controlled trial of donepezil in patients with Alzheimer's disease. Neurology 1998; 50: 136-145.
- 3. Rogers S, Friedhoff L. Long-term efficacy and safety of donepezil in the treatment of Alzheimer's disease: an interim analysis of the results of a US multicentre open label extension study. Eur Neuropsychopharmacol 1998; 8: 67-75.
- 4. Australian-approved Product Information for Donepezil. Sydney: Pfizer Pty Limited, 10 December 2001.
- 5. Winblad B, Engedal MD, Soininen H, et al. A 1-year, randomized, placebo-controlled study of donepezil in patients with mild to moderate AD. Neurology 2001; 57: 489-495.